B7-33

B7-33 is a synthetic single-chain peptide derived from H2 relaxin, one of the human relaxin hormones best known for its roles in tissue remodeling and connective-tissue softening. It was designed to retain relaxin's anti-fibrotic signaling while simplifying the parent hormone's more complex two-chain structure.

B7-33 is an investigational, animal-stage research compound. It is not an approved medicine in any major jurisdiction, and the effects described in the scientific literature come almost entirely from preclinical cell and animal models rather than from established human therapeutics.

Interest in B7-33 centers on its ability to engage the same receptor system as full-length relaxin while producing a distinct downstream signaling pattern. High-level mechanistic themes studied in the laboratory include:

• Binding to the relaxin family peptide receptor 1 (RXFP1)

• Preferential activation of the ERK1/2 signaling pathway, which is associated with anti-fibrotic and tissue-remodeling effects

• An apparent bias away from some of relaxin's other signaling outputs, which researchers have proposed may narrow its biological footprint

Whether this signaling profile translates into meaningful, durable outcomes in intact organisms — and eventually in humans — remains an open research question rather than an established fact.

B7-33 has no approved medical indication. In the research setting it has been explored as a tool for studying fibrosis, the process in which tissues accumulate excess scar-like extracellular matrix. Preclinical work has examined models of fibrosis in the heart, lung, and kidney, as well as models related to preeclampsia.

Because these investigations are exploratory and confined to laboratory systems, any discussion of B7-33 should be framed as basic and translational research rather than as a validated treatment for any human condition.

B7-33 is not specifically named on prominent public anti-doping lists. However, athletes and support personnel should be aware that anti-doping frameworks such as the WADA Prohibited List include a broad category (S0) for substances that are not approved for human therapeutic use by any government health authority. Investigational peptides can fall under such catch-all provisions.

Anyone subject to sport testing should verify current status directly with the relevant anti-doping authority rather than relying on general educational summaries.

Because B7-33 has not undergone the structured human safety evaluation that approved drugs require, its side-effect profile, tolerability, and long-term effects in people are not established. Relaxin biology touches on cardiovascular tone, connective tissue, and vascular function, so effects on those systems are areas researchers would want to characterize carefully.

The absence of documented adverse effects in early research is not evidence of safety. It reflects how little human data exist. Product quality and sourcing for research compounds also vary widely.

B7-33 is a short single-chain peptide engineered from the B-chain region of H2 relaxin, designed to preserve receptor engagement in a smaller, more stable format than the native two-chain hormone.

This summary describes concepts discussed in research and does not constitute medical advice or any suggestion of how the compound might be used in people.

In research catalogs, B7-33 typically appears as a lyophilized (freeze-dried) powder intended for reconstitution in a laboratory setting. It may be listed near other peptides associated with tissue repair or remodeling themes.

Any structural grouping in this catalog is organizational only and should not be read as an endorsement of specific combinations, regimens, or applications.

The published evidence on B7-33 comes from preclinical studies exploring anti-fibrotic signaling in models of organ fibrosis and related conditions. This work has generated scientific interest in relaxin-derived peptides as research tools for understanding tissue remodeling.

At the same time, the evidence base is early-stage and animal-centric. Findings in cell and animal models frequently do not carry over to humans, so claims about B7-33 should be interpreted with caution. High-level overviews are not a substitute for critical appraisal of the primary literature.

For deeper dives on this peptide, see:

• B7-33 areas of research interest
• B7-33 safety context and unknowns
• B7-33 pharmacology concepts (educational)
• B7-33 research and evidence overview

Future FAQs may cover high-level questions such as how B7-33 relates conceptually to full-length relaxin, why researchers are interested in biased receptor signaling, and how preclinical fibrosis models inform (and fail to fully predict) human biology. Answers will remain educational and non-prescriptive.